Clinical trial · Interventional
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Conducting an Early Phase Clinical Trial to Assess for HPV Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of HPV Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Assess for HPV Antigen Presentation
- description
- Therapeutic Biological Product Mix activity 9vHPV Vaccine 1.0 mL add into BCG Organism 50 MG
- interventionNames
- Biological: 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
Primary outcomes (3)
- measure
- 20 HPV Participants with HPV testing by standard PCR assay
- timeFrame
- Duration at least 28 days
- description
- Negative testing HPV by standard PCR assay after percutaneous 21 days
- measure
- 20 HPV Participants with IGRA blood test with HPV protein antigen
- timeFrame
- Duration at least 28 days
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 24 Years
- Maximum age
- 64 Years
Show eligibility criteria text
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of HPV patients. 20 Cervical HPV Infection Patients Inclusion Criteria: * Cervical HPV Infection Patients * Positive testing HPV by standard PCR assay * HPV infection without symptoms * No clinical signs indicative of oncology * TB negative participant is negative IGRA blood test with TB antigens Exclusion Criteria: * Pregnant * Thrombosis * Bleeding * Allergy * TB positive participant is positive IGRA blood test with TB antigens * Symptoms of HPV infection * Clinical signs suggestive of other infection * Symptoms suggestive of other infection * Clinical signs indicative of oncology * Evidence of critical illness
References
Publications (0)
Data not yet available